- Home
- CPT vs MRNA Comparison
CPT vs MRNA Comparison
Compare CPT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- MRNA
- Stock Information
- Founded
- CPT 1993
- MRNA 2010
- Country
- CPT United States
- MRNA United States
- Employees
- CPT N/A
- MRNA N/A
- Industry
- CPT Real Estate Investment Trusts
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPT Real Estate
- MRNA Health Care
- Exchange
- CPT Nasdaq
- MRNA Nasdaq
- Market Cap
- CPT 10.9B
- MRNA 9.8B
- IPO Year
- CPT 1993
- MRNA 2018
- Fundamental
- Price
- CPT $99.35
- MRNA $28.14
- Analyst Decision
- CPT Buy
- MRNA Hold
- Analyst Count
- CPT 18
- MRNA 15
- Target Price
- CPT $122.99
- MRNA $37.15
- AVG Volume (30 Days)
- CPT 985.3K
- MRNA 8.5M
- Earning Date
- CPT 11-06-2025
- MRNA 11-06-2025
- Dividend Yield
- CPT 4.14%
- MRNA N/A
- EPS Growth
- CPT N/A
- MRNA N/A
- EPS
- CPT 1.43
- MRNA N/A
- Revenue
- CPT $1,570,124,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- CPT $2.74
- MRNA N/A
- Revenue Next Year
- CPT $2.57
- MRNA $11.12
- P/E Ratio
- CPT $68.15
- MRNA N/A
- Revenue Growth
- CPT 0.75
- MRNA N/A
- 52 Week Low
- CPT $97.17
- MRNA $23.15
- 52 Week High
- CPT $127.65
- MRNA $57.69
- Technical
- Relative Strength Index (RSI)
- CPT 26.34
- MRNA 39.59
- Support Level
- CPT $97.17
- MRNA $25.57
- Resistance Level
- CPT $105.96
- MRNA $27.37
- Average True Range (ATR)
- CPT 1.67
- MRNA 1.14
- MACD
- CPT -0.35
- MRNA -0.32
- Stochastic Oscillator
- CPT 2.50
- MRNA 6.38
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.